期刊文献+

阿尔茨海默氏病相关蛋白质及其作用机制研究进展

Progress in Alzheimer's Disease Related Proteins and Their Pathway Analysis by Proteomics
原文传递
导出
摘要 蛋白质组学技术被广泛的用于阿尔茨海默氏病(AD)的研究中。本文综述了已发现的AD脑组织、外周组织和动物模型中蛋白质差异表达和翻译后修饰变化,结合生物信息学分析结果,初步阐明了参与AD发病机制的关键蛋白质及其信号通路,为深入研究AD的病理生理机制和治疗提供了依据。 Proteomics technologies have been widely used in investigation of Alzheimer's disease (AD). Classical methods with protein separation follow by identification provide a convenient platform for quantification of protein level and detection of modification. With the application of novel protein microarrays, mass spectrometry, biochemistry and molecular biology, proteomics technologies show great potentials to study the mechanism of AD and drug targets. We analyzed different protein expression and posttranslational modification found in AD brain, peripheral tissues and animal models. The changed protein function and the main pathway involved were discussed. This article provided new understanding of biochemistry, pathology, and physiology of AD and also supplied insight into potential molecular mechanism of AD.
出处 《现代生物医学进展》 CAS 2009年第18期3594-3597,共4页 Progress in Modern Biomedicine
关键词 阿尔茨海默氏病 蛋白质组学 通路 作用机制 Alzheimer s Diseases Proteomics Pathway Mechanisms
  • 相关文献

参考文献19

  • 1Wimo A, Winblad B, Aguero-Torres H, et al. The magnitude of dementia occurrence in the world[J].Alzheimer Dis Assoc Disord, 2003, 17(2): 63-7.
  • 2Wilson KE, Marouga R, Prime JE, et al. Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labeling[J]. Proteomics, 2005, 5(15): 3851-8.
  • 3Zhang J, Goodlett DR, Quinn .IF, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease [J]. J Alzheimers Dis, 2005, 7(2): 125-33.
  • 4Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with ncurodegencrativc disorders[J]. J Alzheimers Dis, 2006, 9(3) 293-348.
  • 5Wang Q, Woltjer RL, Cimino PJ, et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein [J]. Faseb J, 2005, 19(7): 869-71.
  • 6Lopez MF, Mikulskis A, Kuzdzal S, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures [J]. Clin Chem, 2005, 51 (10): 1946-54.
  • 7Castegna A, Aksenov M, Aksenova M, et al. Proteomic identification of oxidatively modified proteins in Alzheimefs disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terrnihal hydrolase L-1[J]. Free Radic Biol Med, 2002, 33(4): 562-71.
  • 8Lauderback CM, Hacker JM, Huang FF, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abetal-42 [J]. J Neurochem, 2001, 78(2): 413-6.
  • 9Bush AI, The metallobiology of Alzheimer's disease [J]. Trends Neu- rosci, 2003, 26(4): 207-14.
  • 10Kouchi Z, Sorimachi H, Suzuki K, et al. Proteasome inhibitors induce the association ofAlzheimer's amyloid precursor protein with Hsc73 [J]. Biochem Biophys Res Commun, 1999, 254(3): 804-10.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部